Market Overview

UPDATE: Credit Suisse Upgrades Aetna

Related AET
KeyBanc: 6 Reasons To Buy Teladoc
The Week Ahead: AMD's Ryzen Anniversary Webinar, CVS Votes On Aetna Merger
CVS Health - Short-Term Pain For Long-Term Gain (Seeking Alpha)

In a report published Thursday, Credit Suisse analyst Chris Carter upgraded Aetna (NYSE: AET) from Neutral to Outperform, raising its price target to $83.00 from $69.00.

According to the report, as an upside is seen to 2014 guidance from a continuation of muted cost trends and potential for additional CVH synergy, AET has been upgraded to Outperform.

“Moreover, while there is uncertainty associated with hc reform, our analysis around new exchange lives and Medicaid expansion gives us comfort that any potential downside risk is limited and/or manageable,” the report said. “We are raising our estimates and increasing our TP to $83 (from $69), and view discounted valuation as attractive. Aetna is our new top pick in Managed Care and the Credit Suisse Investment Policy Committee (IPC) is adding AET to the U.S. Focus List.”

Some highlights from the report included:

-Muted cost trends expected to persist. -Comfort in downside risk. -CVH deal provides upside.

AET closed Wednesday at $69.72 with shares trading up at 1.02 percent.

Latest Ratings for AET

Jan 2018Credit SuisseMaintainsNeutralNeutral
Jan 2018Deutsche BankUpgradesHoldBuy
Jan 2018PiperJaffrayUpgradesNeutralOverweight

View More Analyst Ratings for AET
View the Latest Analyst Ratings

Posted-In: Chris Carter Credit SuisseAnalyst Color Upgrades Analyst Ratings


Related Articles (AET)

View Comments and Join the Discussion!